Status and phase
Conditions
Treatments
About
This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving fat and inflammation (steatohepatitis) as well as fibrosis in subjects with non alcoholic steatohepatitis (NASH). as well as the safety and tolerability of AXA1125. Subjects will take one of two different doses of AXA1125 or a placebo twice daily, and a liver biopsy will be done at the beginning and end of the 48-week study.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
273 participants in 3 patient groups, including a placebo group
Loading...
Central trial contact
Margaret Koziel, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal